Afrezza: Fast-Acting Inhaled Insulin

• Autores: Diane S. Aschenbrenner
• Localización: American Journal of Nursing, ISSN 0002-936X, Vol. 114, Nº. 10, 2014, págs. 22-23
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • * Afrezza (insulin human) is a newly approved fast-acting inhaled insulin. It can be used in treating type 1 diabetes when added to a long-acting insulin; in studies, patients with type 2 diabetes used it in combination with oral antidiabetic therapy. Afrezza will be available in 2015.

    * Afrezza is taken before meals using a small, specially designed inhaler.

    * Patients should be carefully assessed for lung disease prior to starting Afrezza therapy. Chronic obstructive pulmonary disease and asthma are contraindications to use. Lung function can deteriorate after therapy begins.